Organon acquisition buzz brings Sun Pharma deal strategy back
In a clarification filed on January 19, Sun Pharma said there was “no material event or information” requiring disclosure under Regulation 30 of the Listing Regulations. The company added that it would inform stock exchanges of any material developments in line with regulatory requirements.
In a clarification filed on January 19, Sun Pharma said there was “no material event or information” requiring disclosure under Regulation 30 of the Listing Regulations. The company added that it would inform stock exchanges of any material developments in line with regulatory requirements.
What's Your Reaction?
Economist Admin
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
